Drugs & Targets FDA publishes draft guidance to accelerate biosimilar development and lower costs October 31, 2025Vol.51 No.40
Drugs & Targets EC approves Keytruda combination for a head-and-neck indication October 31, 2025Vol.51 No.40
Drugs & Targets FDA approves Blenrep combination for relapsed/refractory multiple myeloma after two or more lines of therapy October 24, 2025Vol.51 No.39
Drugs & Targets CHMP adopts positive opinion for Libtayo as adjuvant treatment for high-risk CSCC October 24, 2025Vol.51 No.39
Drugs & Targets FDA requires a boxed warning for immune effector cell-associated enterocolitis following Carvykti treatment October 17, 2025Vol.51 No.38
Drugs & Targets ARPA-H selects Tempus as contract research organization for ADAPT Program October 17, 2025Vol.51 No.38
Drugs & Targets Algen Biotechnologies, AstraZeneca form AI drug discovery partnership October 17, 2025Vol.51 No.38
Drugs & Targets FDA approves Libtayo for adjuvant treatment of cutaneous squamous cell carcinoma October 10, 2025Vol.51 No.37
Drugs & Targets FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC October 03, 2025Vol.51 No.36
Drugs & Targets FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer October 03, 2025Vol.51 No.36
